BPI

Across TCGA pan-cancer cohorts, BPI mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BPI data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BPI mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated BPI expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where BPI mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	1.000	0.872	.011	15	view →
LUAD	OS	Tertile	III,IV	0.360	0.848	.004	12	view →
PDAC	OS	Quartile	III,IV	0.259	0.868	.008	6	view →
LSCC	DFS	Tertile	All	0.839	0.338	.016	4	view →
UCEC	DFS	Median	All	1.000	0.935	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BPI–CCRCC (DFS)

Open the CCRCC breakdown →